

TEM-PCR Awards & Recognition



Target Enriched Multiplex Polymerase Chain Reaction

- In 2006 **TEM-PCR** was awarded the runner up for the **Wall Street Journal Medical Technology Innovation of the Year Award**

- In 2006 **TEM-PCR** was awarded the **Frost and Sullivan Award for Technology Innovation and Leadership of the Year Award in Molecular Diagnostics in the European Union**

- In 2009 **DIATHERIX Laboratories** was awarded the **Technology Innovation Award for the First Commercially Available H1N1-09 test performed in a CLIA laboratory, made possible by TEM-PCR**

- In 2010 **Podiatry Today** listed **TEM-PCR** as one of its **Top Ten Innovations in Podiatric Care**. The only laboratory service to make the list.

Tem-PCR is the first technology introduced to the clinical market that can identify multiple pathogens, both viral and bacterial, detect co-infections, identify specific toxin producing genes and determine highly transferable genetic drug resistances at the same time in one test panel.

DIATHERIX'S testing process, called Target Enriched Multiplex Polymerase Chain Reaction (Tem-PCR), uses molecular differential diagnostic (MDD) technology. Tem-PCR is the first test introduced to the clinical market that in a single result can identify multiple pathogens, both viral and bacterial; detect co-infections and determine their genetic drug resistance.